Business
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11,
About this update from Immix Biopharma, Inc.
[{"type":"text","content":"Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023\nLOS ANGELES, CA, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at the upcoming European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting to be held in Rotterdam, Netherlands February 9-11, 2023. “We are delighted to be presenting additional clinical data at the upcoming at European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting,” said Polina Stepensky, MD, Director of the Hadassah Medical Organization's Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator. “As we continue to accumulate clinical data, we are learning more about the potential for this therapy to treat multiple myeloma and AL amyloidosis.” Posters to be presented: “Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center” Nexcella, Inc. previously announced that NXC-201 (formerly HBI0101) produced 85% overall response rate (ORR) and 71% complete response/stringent complete response (CR/sCR) at the therapeutic dose from the first 20 patients in an ongoing phase 1b/2a relapsed/refractory multiple myeloma ongoing clinical trial as of the June 27, 2022 data cutoff with a median of 6 (range, 3-13) prior lines of therapy. NXC-201 also produced 100% ORR and 100% organ response rate in 4 relapsed/refractory AL Amyloidosis patients as of the February 26, 2022 AL Amyloidosis manuscript publication date. In addition, zero neurotoxicity of any grade was observed and zero events of immune effector cell-associated neurotoxicity syndrome (ICANs) were observed with NXC-201 treatment. These data were published in Haematologica https://doi.org/10.3324/haematol.2022.281628 (multiple myeloma) and Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637 (AL amyloidosis). Low-grade (grade 1/2) CRS duration of median 2 days with median onset of ...